In an effort to provide you with timely market feedback from the 2016 ASCO Annual Meeting, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ conducted immediately after the meeting. This report explores skin cancer (melanoma and merkel cell carcinoma) presentations concerning the use of checkpoint inhibitors and the combination of BRAF and MEK inhibitors.
Conclusions: Immediate Impact of 2016 ASCO Presentations on Clinical Practice for Melanoma and Merkel Cell Carcinoma
For a more detailed analysis report, please click here to download the full report.
Submitted by Robert Stephan, VP, Research and Physician Society, and Jan Heybroek, President MDoutlook.
You must be logged in to post a comment